NCT04854746View on ClinicalTrials.gov

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

January 4, 2022

Study Completion Date

January 4, 2022

Conditions
Norovirus Infections
Interventions
BIOLOGICAL

VXA-GI.1.NN

GI.1 oral vaccine tablet

BIOLOGICAL

Placebo Tablet

Tablets matching in number and appearance to active vaccine tablets

Trial Locations (3)

70006

Benchmark Research, New Orleans

78705

Benchmark Research, Austin

90630

WCCT, Cypress

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT04854746 - Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine | Biotech Hunter | Biotech Hunter